Showing results (121-130 of 147) with videos related to
Sort By:
Pageof 15
Melanoma Research|May 17, 2019
Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient ProgramSalvador Martin-Algarra, Rebecca Hinshelwood, Soizick Mesnage, et al.Oncotarget|November 3, 2015
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanomaElin S Gray, Helen Rizos, Anna L Reid, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.Cancer Treatment and Research Communications|July 30, 2021
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancerEmiliano Calvo, Alexander Spira, María de Miguel, et al.Lancet (London, England)|June 28, 2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Jean-Jacques Grob, Lev V Demidov, et al.JCO Precision Oncology|August 29, 2024
Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for DeliveryKortnye Smith, Sophie O'Haire, Benjamin Markman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorKevin B Kim, Richard Kefford, Anna C Pavlick, et al.European Journal of Cancer (Oxford, England : 1990)|December 12, 2022
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomesJoanna Lee, Tasnia Ahmed, Andrea Maurichi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid TumorsJayesh Desai, Hui Gan, Catherine Barrow, et al.European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.Pageof 15